VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
NCT00045266 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2016-06-03
Summary
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.
Conditions
- Lymphoma
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
- BIOLOGICAL
-
ziv-aflibercept
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - lead INDUSTRY
Principal Investigators
-
Jakob Dupont, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Purpose
- TREATMENT
- Masking
- NONE
Eligibility
- Min Age
- 25 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-04-30
- Primary Completion
- 2007-02-28
Countries
- United States
Study Locations
More Related Trials
-
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
NCT01336920 ·Status: COMPLETED ·Phase: PHASE1
-
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
NCT01016990 ·Status: UNKNOWN ·Phase: PHASE2
-
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
NCT00644124 ·Status: COMPLETED ·Phase: PHASE1
-
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
NCT00621452 ·Status: COMPLETED ·Phase: PHASE1
-
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
NCT00055640 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
NCT05144841 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01421667 ·Status: COMPLETED ·Phase: PHASE2
-
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
NCT05162976 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
NCT00866047 ·Status: COMPLETED ·Phase: PHASE2
-
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
NCT00005950 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00007865 ·Status: COMPLETED ·Phase: PHASE2
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT05618366 ·Status: TERMINATED ·Phase: PHASE1
-
Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma
NCT00002501 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
NCT03277729 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
NCT05202782 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
NCT04205409 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
NCT00458731 ·Status: COMPLETED ·Phase: PHASE1
-
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT06210750 ·Status: WITHDRAWN ·Phase: PHASE2
-
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05633615 ·Status: RECRUITING ·Phase: PHASE2
-
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
NCT05418088 ·Status: RECRUITING ·Phase: PHASE1
-
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00004197 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00005601 ·Status: COMPLETED ·Phase: PHASE2
-
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00077155 ·Status: COMPLETED ·Phase: PHASE1
-
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00062296 ·Status: COMPLETED ·Phase: PHASE2
-
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
NCT04447716 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1